MDXG

The model outputs a Neutral rating for MiMedx (cannabinoid program), scoring 41/100 at conviction 3 of 5. Fundamentals carry 35 percent of the model, regulatory posture 25, market signal 25, and editorial density 15, with every pillar contribution auditable. Regulatory leads the pillar table at 49, and is the main lever behind the Neutral conclusion. The offset comes from editorial at 30, which pulls the composite toward the middle of the band.

Coverage inputs are partial for MiMedx (cannabinoid program), so the composite tilts toward the pillars that are well-populated — jurisdictional posture and filing cadence — while the fundamentals contribution stays capped. All inputs are drawn from primary regulatory filings, licensed fundamentals data, institutional pricing feeds, and CIN newsroom coverage density. Because every ticker in the CIN universe is scored on the same 336-name basis, MiMedx (cannabinoid program) slots into a direct comparison rather than a bespoke narrative, and the score refreshes on the primary-source ingest cadence.

Regulatory posture is where the rating breathes. That pillar contributes 49, and a step-up in filing frequency without any enforcement activity would be the cleanest catalyst for a tighter reading.